<DOC>
	<DOCNO>NCT02013115</DOCNO>
	<brief_summary>Infants show high local pulmonary inflammation diagnosted respiratory distress syndrome usually need second pulmonary surfactant easier develop Brochopulmonary . Cursurf use worldwide infant respiratory distress syndrome , Budesonide glucocorticoid high local anti-inflammatory effect.Our hypothesis Cursurf combine Budesonide could reduce need Cursurf incidence Brochopulmonary dysplasia .</brief_summary>
	<brief_title>Curosurf/Budesonide Infants With Respiratory Distress Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Poractant alfa</mesh_term>
	<criteria>Clinical diagnosis respiratory distress syndrome pneumothorax surgical disease major congenical defect</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Hours</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>infant</keyword>
	<keyword>respiratory distress syndrome</keyword>
</DOC>